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Abstract
Chemokine (C-C motif) ligand 2, also known as monocyte chemoattractant protein 1 (MCP-1) is an important factor
for the pathogenesis of HIV-associated neurocognitive disorders (HAND). The mechanisms of MCP-1-mediated
neuropathogenesis, in part, revolve around its neuroinflammatory role and the recruitment of monocytes into the
central nervous system (CNS) via the disrupted blood-brain barrier (BBB). We have previously demonstrated that
HIV-1/HIV-1 Tat upregulate platelet-derived growth factor (PDGF)-BB, a known cerebrovascular permeant;
subsequently, the present study was aimed at exploring the regulation of MCP-1 by PDGF-BB in astrocytes with
implications in HAND. Specifically, the data herein demonstrate that exposure of human astrocytes to HIV-1 LAI
elevated PDGF-B and MCP-1 levels. Furthermore, treating astrocytes with the human recombinant PDGF-BB protein
significantly increased the production and release of MCP-1 at both the RNA and protein levels. MCP-1 induction
was regulated by activation of extracellular-signal-regulated kinase (ERK)1/2, c-Jun N-terminal kinase (JNK) and p38
mitogen-activated protein (MAP) kinases and phosphatidylinositol 3-kinase (PI3K)/Akt pathways and the
downstream transcription factor, nuclear factor κB (NFκB). Chromatin immunoprecipitation (ChIP) assays
demonstrated increased binding of NFκB to the human MCP-1 promoter following PDGF-BB exposure. Conditioned
media from PDGF-BB-treated astrocytes increased monocyte transmigration through human brain microvascular
endothelial cells (HBMECs), an effect that was blocked by STI-571, a tyrosine kinase inhibitor (PDGF receptor
(PDGF-R) blocker). PDGF-BB-mediated release of MCP-1 was critical for increased permeability in an in vitro BBB
model as evidenced by blocking antibody assays. Since MCP-1 is linked to disease severity, understanding its
modulation by PDGF-BB could aid in understanding the proinflammatory responses in HAND. These results suggest
that astrocyte activation by PDGF-BB exaggerates monocyte recruitment into the brain via MCP-1 and underscores
the critical role astrocytes play in HAND.
Background
HIV-associated neurocognitive disorders (HAND) re-
main a common complication of HIV infection affecting
up to 60% of infected individuals despite the use of anti-
retroviral therapy (ART) [1]. With the advancement of
ART the prevalence of HAND has actually increased,
partly due to both increased survival rates of HIV-
infected individuals and to the reduced ability of most of
these drugs to cross the blood–brain barrier (BBB).
Among the factors involved in the pathogenesis of
HAND, influx of HIV-infected monocytes in response to
the chemokine monocyte chemoattractant protein 1
(MCP-1) via a breached endothelial barrier, plays a crit-
ical role in disease pathogenesis. MCP-1 plays a vital role
in the recruitment of monocytes into the brain contrib-
uting to neuroinflammation and BBB disruption [2,3].
This chemokine has been extensively studied and is
expressed by a number of cell types including astrocytes,
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microglia and neurons [4,5]. Elevated expression of
MCP-1 has been demonstrated in various diseases in-
cluding multiple sclerosis, amyloid lateral sclerosis, lupus
nephritis, peripheral neuropathy and Alzheimer’s disease
[6-13]. While increased expression of MCP-1 has been
shown to correlate with HIV-associated central nervous
system (CNS) complications, regulation of this chemo-
kine in the context of HIV disease remains less clear.
Understanding the molecular mechanisms modulating
MCP-1 may thus provide insights into development of
therapeutic targets for many neurodegenerative diseases
including HAND.
Platelet-derived growth factor (PDGF) is a well known
and potent inducer of MCP-1. The PDGF family of pro-
teins is very closely related to the vascular endothelial
growth factor (VEGF) family and is highly conserved
throughout the animal kingdom [14]. These proteins are
usually expressed as dimers: PDGF-A and PDGF-B can
form homodimers or heterodimers, and PDGF-C and
PDGF-D form homodimers. For the sake of clarity, in
this study, PDGF-B refers to the RNA expression,
whereas PDGF-BB refers to the protein expression of
these genes. Many studies on PDGF have focused pri-
marily on its mitogenic effects [15-17], however, diver-
gent effects of PDGF are rapidly emerging. For example,
recent studies by Lawrence et al. have demonstrated
PDGF to be a cerebrovascular permeant that can disrupt
BBB integrity during ischemic stroke conditions [18].
Along similar lines, it has been shown that PDGF-BB
can disrupt BBB via the modulation of molecules im-
portant in maintaining tight junctions such as ZO-1 and
adhesion molecules [19].
Since astrocytes are a major source of MCP-1 in the
brain and PDGF-BB has been shown to be an inducer of
MCP-1, the purpose of this study was to explore the
modulation of MCP-1 by PDGF-BB released from HIV-
treated astrocytes. We hypothesize that PDGF-BB
induced by HIV-1/HIV-1 Tat can result in astrocytic ac-
tivation and release of MCP-1 and BBB disruption. The
data demonstrate that the exposure of human astrocytes
to HIV-1 LAI resulted in the induction of PDGF at both
the mRNA and protein levels. To explicate the mechan-
ism/s involved in PDGF-BB/MCP-1 interaction, human
astrocytes were then treated with PDGF-BB and moni-
tored for expression of MCP-1. Utilizing pharmaco-
logical and genetic approaches we demonstrate the
involvement of extracellular-signal-regulated kinase
(ERK)1/2, c-Jun N-terminal kinase (JNK) and p38
mitogen-activated protein kinases (MAPKs), Phosphati-
dylinositol 3-kinase (PI3K)/Akt pathways and the tran-
scription factor nuclear factor κB (NFκB) in PDGF-BB-
mediated induction of MCP-1 in astrocytes. Because
both PDGF-BB and MCP-1 are known to affect the BBB
and since astrocytic end-feet processes are in close
contact with the endothelia, we also addressed the func-
tional implications this may have on the BBB. Using
pharmacological and neutralizing antibody approaches,
we reveal that both PDGF-BB and MCP-1 play critical
roles in reducing the integrity of the BBB. These data
highlight the role of PDGF-BB in astrocytic release of
MCP-1, which in turn, is critical for recruitment of
monocytes across the BBB. Taken together, these studies
underscore the role of PDGF signaling as a potential
therapeutic target of HAND.
Materials and methods
Materials
Recombinant human PDGF-BB was purchased from
R&D Systems (Minneapolis, MN, USA). All experiments
involving the treatment of cells with exogenous PDGF-
BB were conducted under serum-free conditions because
serum induces PDGF. STI-571, an inhibitor of tyrosine
kinase receptors, was obtained from Novartis (Basel,
Switzerland). The specific phosphatidinylinositol-3’ kin-
ase (PI3K) inhibitor LY294002, mitogen-activated pro-
tein (MAP) kinase kinase (MEK) inhibitor U0126 and
p38 mitogen activated kinase (p38) inhibitor SB203558
were purchased from Promega (Madison, WI, USA).
The JNK inhibitor SP600125 was purchased from Assay
Designs (Ann Arbor, MI, USA). MCP-1 neutralizing
antibody was obtained from eBioscience (San Diego,
CA, USA). The C-C chemokine receptor type 2 (CCR2)
antagonist, RS 102895, was purchased from Sigma (St
Louis, MO, USA). The chromatin immunoprecipitation
(ChIP) assay kit was obtained from Upstate, (Billerica,
MA, USA).
Cell culture and cell lines
The human astrocytic cell line A172 (no. CRL-1620;
American Type Culture Collection (ATCC)) were cul-
tured as described previously [20] and maintained in
Dulbecco's modified Eagle’s medium (DMEM) high glu-
cose medium containing 10% heated-inactivated fetal
bovine serum, 2 mM glutamine, penicillin (100 units/
ml), streptomycin (100 μg/ml), essential amino acids and
vitamins. In this study, A172 cells were used within 30
passages. Human primary astrocytes were obtained from
ScienCell Research Laboratories (Carlsbad, CA, USA)
and were cultured in DMEM/F12 medium (Invitrogen
Life Technologies, Carlsbad, CA, USA) containing 10%
heat-inactivated fetal bovine serum (FBS), 2 mM glutam-
ine, sodium bicarbonate, gentamicin, non-essential
amino acids and vitamins. Primary human brain micro-
vascular endothelial cells (HBMECs) obtained from
Dr Monique Stins (The Johns Hopkins University,
Baltimore, MD) were cultured in RPMI 1640 medium
containing 10% heat-inactivated fetal bovine serum,
10% Nu-Serum, 2 mM glutamine, 1 mM pyruvate,
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penicillin (100 U/ml), streptomycin (100 μg/ml), essen-
tial amino acids, and vitamins according to our previous
publication [21].
Cell treatment
Human astrocytes were serum starved overnight prior to
treatment. The HIV-1 LAI used in this study was propa-
gated in stimulated peripheral blood mononuclear cells
(PBMCs) [22] (supplied by Dr Howard Gendelman, Uni-
versity of Nebraska Medical Center, Omaha, NE, USA).
The rationale for using a C-X-C chemokine receptor
type 4 (CXCR-4)-tropic virus is based upon previous
studies demonstrating the susceptibility of astrocytes to
CXCR4-tropic viruses [23,24]. In the pharmacological
inhibitor studies, the cells were pretreated with inhibi-
tors specific for MEK (U0126, 1 μM), JNK (SP600125,
10 μM), P38 (SB20358, 1 μM) and PI3K (LY294002, 1
μM) for 1 h prior to PDGF-BB exposure. The inhibitors
were not removed from the astrocytes during PDGF-BB
treatment and concentrations utilized in this study were
based upon our previous studies [25].
MCP-1 protein analysis by enzyme-linked immunosorbent
assay (ELISA)
MCP-1 levels were examined using an MCP-1 ELISA kit
purchased from R&D Systems. Samples were analyzed
for MCP-1 protein according to the manufacturer’s
instructions in triplicates determined in at least three in-
dependent experiments.
Reverse transcription and real-time RTPCR (RT-PCR)
Total RNA was extracted using Trizol reagent according
to the manufacturer’s protocol (Invitrogen). RNA (1 μg)
was used for cDNA production according to manufac-
turer’s instructions (Thermo Scientific, Waltham, MA,
USA). The sequences of primers used for human MCP-1
(GenBank accession number NM 002982) were as fol-
lows: sense: CAGCAGGTGTCCCAAAGAAGCTGT
antisense: CCATTCCTTATTGGGGTCAGCACAGA.
The sequences of primers used for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (GenBank accession
number NM 002046) were as follows: sense: TGCACC
ACCAACTGCTTAGC; antisense: GGCATGGACTGTG
GTCATGAG. The primers for CCR2 (GenBank acces-
sion number NM 001123396) were as follows: first
round sense: TCTGGAGACCTCAACCAAATG; anti-
sense: GGAAATGCGTCCTTGTTCAA. The primers used
in the second round were as follows: sense: CCCTGTAT
CTCCGCCTTCACT; antisense: TTCAGCTTGTGGC
TTGTCTCA. Quantitative analyses of mRNA were con-
ducted using an ABI 7500 Fast Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA). The primers
for PDGF-B, MCP-1 and 18S were purchased from SA
Biosciences (Frederick, MD, USA). Data were normalized
using Ct values for GAPDH or 18S in each sample. To cal-
culate relative amounts mRNA, the average Ct values were
subtracted from GAPDH or 18S values for each target
gene to provide changes in Ct value. Fold change in ex-
pression was calculated as log2 relative units.
Flow cytometry
Untreated human primary astrocytes and A172 human
astrocytes were collected in cold phosphate-buffered sa-
line (PBS) and ethylenediaminetetra-acetic acid (EDTA)
(5 mM) followed by incubation with anti-PDGF receptor
α (PDGF-Rα) (CD140α; 1:5) and anti-PDGF-Rβ (CD140β;
1:5) BD LSR II (BD Biosciences, San Jose, CA, USA) was
used for fluorescence acquisition, and data were analyzed
with FACS Diva software (BD Biosciences).
Western blotting
PDGF-BB treated astrocytes were lysed using the Mam-
malian Cell Lysis kit (Sigma) and the NE-PER Nuclear
and Cytoplasmic Extraction kit (Pierce, Rockford, IL,
USA) as per manufacturer’s instructions. Cell lysates
were subjected to separation by 12% sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) (30
μg protein per well) and transferred to polyvinylidene
difluoride (PVDF) membranes. The blots were blocked
with 5% non-fat dry milk in PBS. Western blots were
then probed with antibodies recognizing phosphorylated
forms of ERK1/2, JNK, p38 and Akt and total forms of
ERK1/2, JNK, and Akt (Cell Signaling, Danvers, MA,
USA; 1:500); NFκB-p65 and phosphorylated inhibitor of
κB (pIκB) Cell Signaling, (1:1,000); Histone (1:1,000) and
β-actin antibodies (Santa Cruz Biotechnologies, Santa
Cruz, CA, USA; 1:5,000). Signals were detected by
chemiluminescence (Pierce).
Transduction with adenoviral constructs
A172 cells were infected with adenoviral constructs con-
taining either wild-type (WT) or dominant-negative
(DN) forms of Akt (a kind gift from Dr K Walsh, Tufts
University School of Medicine, Boston, MA, USA). In
addition, cells were also transduced with recombinant
adenoviral vectors expressing full-length p65/RelA or
p65/RelA mutant (RelA 1–300) (a kind gift from Dr S
Maggiwar, University of Rochester Medical Center,
Rochester, NY, USA) used at a multiplicity of infection
(MOI) of 50 as previously described [26]. Astrocytes
infected for 24 h with adenoviral constructs were subse-
quently treated with PDGF-BB, followed by assessment
by western blotting or ELISA.
Short interfering RNA transfection of astrocytes
Short interfering RNA (siRNA) targeted against PDGF-
Rβ was obtained from Dharmacon (Boulder, CO, USA).
Human A172 cells were plated in 24-well plates at a
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density of 4 × 104 cells per well 1 day prior to trans-
fection. Cell culture medium was replaced with 250 ml
pre-warmed OPTI-MEM I culture medium. Lipofectamine-
2000 reagent (Invitrogen) was then combined with
serum-free medium for 5 minutes at room temperature.
The PDGF-Rβ siRNA was then added into the mixture
described above to a final concentration of 5 μM. Then,
siRNA and the reagent mixture were incubated for 20
minutes at room temperature, after which, the combined
mixture was added to the cells. The cell culture plate
was shaken gently for 5 s and incubated for 24 h at 37°C.
Knockdown efficiency (Figure 1D) of the transfected
astrocytes were (54%) as determined by RT-PCR.
Transfection with plasmid constructs
DN and WT constructs of MEK were provided by Dr
Young Han Lee (Konkuk University, Korea). A172 cells
were transfected with plasmid constructs containing ei-
ther WT or DN forms of MEK as described above. The
transfection efficiency was 42% as determined by immu-
nostaining (data not shown).
ChIP assay
The ChIP assay was performed according to the manu-
facturer’s instructions (Upstate, Billerica, MA, USA) with
slight modifications. After treatment of the cells, 18.5%
fresh formaldehyde was added directly into the medium
at a final concentration of 1% formaldehyde and incu-
bated for 10 minutes at room temperature, followed by
quenching with 125 mM glycine. The cells were then
scraped using 2 ml pre-chilled PBS containing 1 × prote-
ase inhibitor mixture. The cell pellet was harvested by
spinning at 800 g at 4°C, and lysis buffer was added (pro-
vided in the kit) to harvest nuclei. DNA was then
sheared by sonication. A total of 50 μl of the sheared
crosslinked chromatin was then mixed with 20 ml pro-
tein A magnetic beads and 5 mg of immunopreciptating
Abs against NFκB p65, acetyl histone H3 (as a positive
control), and normal rabbit IgG (as a negative control)
diluted in 450 ml dilution buffer overnight at 4°C. The
magnetic beads binding Ab-chromatin complex was
then washed with 0.5 ml each of a series of cold wash
buffers in the order of low salt buffer, high salt buffer,
LiCl buffer, and Tris-EDTA buffer. The crosslinking of
protein-DNA complexes were reversed to free DNA by
incubation at 62°C for 2 h and purified using DNA puri-
fication spin columns following the manufacturer’s
instructions. Finally, the purified DNA was amplified (35
cycles) via PCR to identify the promoter region contain-
ing NFκB binding site ‘GGGCCTTTCC’. The sequence
of the primers used to identify the MCP-1 promoter
bound to NFκB were as follows: sense: GCATCAGAGC
ATTGACCCTCA; antisense: AGGTCAGTGCTGGCG
TGAGA.
Monocyte isolation and transmigration
Primary HBMECs seeded on 6.5 mm polyester transwell
inserts (5.0 μm pore size) were grown to confluence.
Following confluency, conditioned media from primary
astrocytes treated with PDGF-BB was added to the bot-
tom chamber of the transwell and allowed to incubate at
37°C in a humid atmosphere of 5% CO2 for 24 h. MCP-
1 neutralizing antibody was added to PDGF-BB treated
conditioned media prior to HBMEC exposure for 24 h.
Monocytes were obtained from HIV-1, HIV-2 and hepa-
titis B seronegative donor leukopacks, and separated by
countercurrent centrifugal elutriation as previously
described [27]. Monocytes were washed with PBS and
fluorescently labeled with 10 μM Cell tracker green
(Invitrogen) for 10 minutes at room temperature. Labeled
cells (2 × 105 cells) were added to the upper compart-
ments of transwell inserts and allowed to transmigrate at
37°C in a humid atmosphere of 5% CO2 for 24 h. Trans-
migrated monocytes were quantified using florescent
plate reader (435 nm/528 nm excitation/emission).
Statistical analysis
Statistical analysis was performed using one-way analysis
of variance (ANOVA) with a post hoc Student’s t test.
Results were judged statistically significant if P <0.05 by
analysis of variance.
Results
HIV-1-mediated upregulation of PDGF-B and MCP-1 in
astrocytes
Since astrocytes in the CNS are exposed to HIV-1, we
first sought to examine the modulation of PDGF-B and
MCP-1 by HIV-1. Purified HIV-1 LAI virus obtained by
high-speed ultracentrifugation and resuspended in astro-
cyte serum-free media was used for these experiments.
Serum-starved astrocytes were exposed to purified virus
at a MOI of 0.1 for 6 h followed by assessment of RNA
levels by real-time RT-PCR. The MOI of HIV-1 LAI
used was based upon our previous study [25]. As shown
in Figure 2A, HIV-1 LAI significantly upregulated both
PDGF-B (1.7-fold) and MCP-1 (twofold) mRNA levels.
To confirm whether increased mRNA levels of PDGF-B
translated into increased protein, a western blot analysis
was performed on lysates of astrocytes exposed to HIV-1
LAI for 24 h. As shown in Figure 2B exposure to HIV-1
LAI also induced upregulation of PDGF-BB protein.
Likewise, supernatants from A172 cells treated with HIV
LAI were analyzed for MCP-1 levels via ELISA. As
shown in Figure 2D, HIV-1 LAI exposure also resulted
in increased MCP-1 levels. To determine whether HIV-
mediated induction of MCP-1 could, in part, be
explained due to increased PDGF-BB levels, astrocytes
were treated with the PDGF receptor blocker STI-571
for 1 h prior to HIV-1 exposure and assessed for MCP-1
Bethel-Brown et al. Journal of Neuroinflammation 2012, 9:262 Page 4 of 14
http://www.jneuroinflammation.com/content/9/1/262
Figure 1 Engagement of platelet-derived growth factor receptor (PDGF-R) is critical for PDGF-BB induced monocyte chemoattractant
protein 1 (MCP-1) expression in astrocytes. (A) Human primary as well as A172 primary astrocytes express both PDGF-α and PDGF-β
receptors. Untreated human primary and A172 astrocytes were subjected to flow cytometric analyses using antibodies against human PDGF-αR
(CD140α) and PDGF-βR (CD140β). (B,C) PDGF-BB-mediated induction of MCP-1 mRNA and protein expression in human primary and A172
astrocytes. (B) Human primary and A172 astrocytes were exposed to PDGF-BB for 6 h. Total RNA isolated from human A172 astrocytes was
subjected to real-time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis using primers for human MCP-1. (C) Supernatant fluid
from astrocytes treated with PDGF-BB for 24 h were assessed for release of chemokine MCP-1 using the human MCP-1 enzyme-linked
immunosorbent assay (ELISA) kit. (D) Total RNA from A172 cells transfected with either nonsense (Non) or PDGF-Rβ short interfering (si)RNAs was
subjected to RT-PCR analysis using primers specific for PDGF-Rβ. (E) siRNA, but not Non siRNA inhibited PDGF-BB-mediated induction of MCP-1
RNA. (F) Supernatants from A172 cells transfected with either Non or siRNAs were subjected to MCP-1 ELISA assay. PDGF-Rβ siRNA, but not Non
siRNA inhibited PDGF-BB-mediated induction of MCP-1 protein. **P <0.01, ***P <0.001 versus control group.
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expression. Blocking the PDGF-R significantly reduced
HIV-mediated induction of MCP-1 RNA (Figure 2C)
and protein (Figure 2D).
PDGF-BB-mediated upregulation of MCP-1 in astrocytes
All experiments involving the treatment of cells with ex-
ogenous PDGF-BB protein were conducted under
serum-free conditions since PDGF promoter is known
to have serum response elements [28,29]. To investigate
the role of PDGF on MCP-1 expression, A172 cells were
treated with recombinant PDGF-BB (20 ng/ml) for the
indicated times and mRNA levels were assessed by RT-
PCR and real-time RT-PCR. The concentration of
PDGF-BB used was based on previous studies [25,30].
Following exposure of A172 astrocytes to PDGF-BB,
there was a time-dependent upregulation of MCP-1
mRNA compared with untreated cells (Figure 3A) with a
peak induction at 6 h post treatment (4.5-fold) and a
subsequent downregulation at 12 h. Similar results were
obtained via real-time PCR (Figure 3B).
To determine whether the increased MCP-1 mRNA
expression correlated with increased protein release in
Figure 2 HIV-1 induces platelet-derived growth factor (PDGF)-B and monocyte chemoattractant protein 1 (MCP-1) mRNA and protein
expression in astrocytes. (A) HIV-1 LAI induced PDGF-B chain and MCP-1 mRNA expression in human A172 astrocytes. Total RNA isolated from
human A172 astrocytes was subjected to real-time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis using primers specific for
human PDGF-B, MCP-1 and 18S. (B) HIV-1 LAI induces PDGF-BB protein expression in human A172 astrocytes. Protein lysates isolated from
astrocytes exposed to HIV-1 were subjected to western blot analysis and analyzed for expression of PDGF-BB protein. (C) HIV-1 LAI induces MCP-1
mRNA levels. Total RNA isolated from human A172 astrocytes was subjected to RT-PCR analysis using primers specific for human MCP-1 and 18S.
(D) HIV-1 LAI induces MCP-1 protein expression in human A172 astrocytes. Supernatants from astrocytes exposed to HIV-1 for 24 h were
subjected to MCP-1 enzyme-linked immunosorbent assay (ELISA) analysis. All the data are presented as mean ± SD of three individual
experiments. *P <0.05, **P <0.01, ***P <0.001 versus control group; ##P <0.01 versus HIV-1-treated group.
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astrocytes, we next examined the MCP-1 protein levels.
Cells were serum-starved as described and treated with
PDGF-BB for 0 to 96 h. Supernatant fluids were col-
lected and MCP-1 protein levels were assessed by
ELISA. As shown in Figure 3C, PDGF-BB upregulated
MCP-1 protein levels in a time-dependent manner with
a continual increase that plateaued at 48 h post treat-
ment. Cumulatively, these data clearly demonstrate that
PDGF-BB treatment mediated the induction of MCP-1
RNA and protein in astrocytes.
Engagement of PDGF-Rβ is critical for PDGF-induced
MCP-1 expression in astrocytes
Because PDGF-BB mediates its effects via binding to its
cognate receptors PDGF-Rα and PDGF-Rβ, our next
step was to examine the role of receptor binding in
PDGF-BB-induced MCP-1 release by astrocytes. How-
ever, before proceeding with this, it was important to
first examine whether astrocytes indeed expressed
PDGF-Rα and PDGF-Rβ. Flow cytometric analysis of
A172 and human primary astrocytes revealed a stark dif-
ference between the two types of cells. As shown in
Figure 1A, of the A172 cells examined, endogenous
levels of PDGF-Rα and PDGF-Rβ were 0.17% and 19.2%,
respectively. Human primary astrocytes expressed higher
levels of PDGF-Rα (4.6%) and lower PDGF-Rβ (10.9%)
levels compared to A172 astrocytes. Despite the differ-
ence in relative distribution of the PDGF receptors,
PDGF-Rβ was the major receptor form expressed in
both types of astrocytes utilized in this study. Similar
results were observed by RT-PCR (data not shown).
Having determined the relative expressions of PDGF-
Rs in both human primary and A172 astrocytes, we next
sought to confirm the effect of PDGF-BB on MCP-1 re-
lease in both cells types. Astrocytes were exposed to
PDGF-BB for 6 h and 24 h for mRNA and protein
Figure 3 Platelet-derived growth factor (PDGF)-BB induces monocyte chemoattractant protein 1 (MCP-1) mRNA and protein expression
in human astrocytes. (A,B) Time-dependence of PDGF-BB-mediated induction of MCP-1 mRNA expression in human A172 astrocytes. Total RNA
isolated from human A172 astrocytes was subjected to reverse-transcriptase polymerase chain reaction (RT-PCR) and real-time RT-PCR analysis
using primers for human MCP-1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S, respectively. PDGF-BB-mediated induction of
MCP-1 mRNA expression peaked at 6 h and decline thereafter. (C) Time-dependence of PDGF-BB-mediated induction of MCP-1 protein
expression in human A172 astrocytes. Supernatant fluid from human A172 cells treated with PDGF-BB for various time points were assessed for
release of chemokine MCP-1 using the human MCP-1 enzyme-linked immunosorbent assay (ELISA) kit. PDGF-BB treatment resulted in a time-
dependent induction of MCP-1 expression. All the data are presented as mean ± SD of three individual experiments. **P <0.01, ***P <0.001 versus
control group; sfm = serum-free media.
Bethel-Brown et al. Journal of Neuroinflammation 2012, 9:262 Page 7 of 14
http://www.jneuroinflammation.com/content/9/1/262
assessment, respectively. As shown in Figure 1B, PDGF-
BB upregulated MCP-1 mRNA levels in both human
A172 as well as human primary astrocytes. MCP-1 pro-
tein ELISA analysis also corroborated this upregulation,
as shown in Figure 1C.
To determine the role that the PDGF-Rs played in
PDGF-BB-mediated MCP-1 release from astrocytes,
human A172 astrocytes were transfected with PDGF-Rβ
siRNA followed by treatment of PDGF-BB and MCP-1
levels were assessed 24 h later. As shown in Figure 1D,
transfection of human A172 cells with PDGF-Rβ siRNA
resulted in efficient knockdown of PDGF-Rβ as demon-
strated by RT-PCR. Cells were transfected with either
PDGF-Rβ siRNA or non-specific (Non) siRNA control
followed by treatment with PDGF-BB for 24 h. PDGF-
BB-mediated induction of MCP-1 mRNA was attenuated
in cells transfected with PDGF-Rβ siRNA but not in the
Non siRNA controls cells (Figure 1E). These results were
further confirmed by examining PDGF-BB-mediated in-
duction of MCP-1 protein levels. As shown in Figure 1F
and as expected, PDGF-BB treatment resulted in
enhanced release of MCP-1 protein in Non siRNA trans-
fected cells but not in cells transfected with PDGF-Rβ
siRNA. Taken together, these findings confirmed the in-
volvement of PDGF-Rs in PDGF-BB-mediated induction
of MCP-1 in astrocytes.
PDGF-BB-mediated induction of MCP-1 involves MAPK
and PI3K/Akt cell signaling pathways
Having determined PDGF-BB-mediated induction of
MCP-1, we next sought to elucidate the signaling path-
ways involved in this process. Since PDGF-BB is a mito-
gen and a pro-survival protein, we examined the
involvement of MAPK and phosphoinositide-3-kinase/
Akt pathways. Human A172 cells were exposed to
PDGF-BB and phosphorylation of MAPK and PI3K/Akt
signaling molecules was assessed by western blotting.
Treatment of astrocytes with PDGF-BB resulted in a
time-dependent increase in phosphorylation of ERK1/2,
JNK, p38 and Akt, with maximal activation at 30 min-
utes following treatment (Figure 4A). Next, to address
the functional implication of MAPK and PI3K/Akt path-
ways in PDGF-mediated induction of MCP-1 expression,
A172 cells were pretreated with inhibitors specific for
the respective signaling pathways followed by PDGF-BB
treatment for 24 h and subsequently assessed for expres-
sion of MCP-1. As shown in Figure 4B, treatment of
cells with the MAPK and PI3K/Akt inhibitors resulted
in amelioration of PDGF-BB-mediated induction of
MCP-1 protein levels.
Further validation of the involvement of the MAPK
pathway in this process was confirmed by transfecting
cells with either the WT or DN constructs of MEK
followed by 24 h treatment with PDGF-BB. PDGF-BB-
mediated induction of MCP-1 was attenuated by DN-
MEK, but not by WT-MEK constructs (Figure 4C). To
confirm the role of PI3K/Akt in PDGF-BB-mediated
MCP-1, A172 cells were transduced with adenoviral
constructs containing either WT or DN forms of Akt.
As shown in Figure 4D, cells transduced with DN Akt
construct failed to upregulate MCP-1 unlike the cells
transduced with the WT Akt construct. Taken together,
these findings confirm the involvement of both MAPK
and PI3K/Akt cascades in PDGF-BB-mediated induction
of MCP-1 in astrocytes.
Involvement of PDGF-Rβ in the regulation of MAPKs and
PI3K/Akt cell signaling pathways
Since PDGF-BB acts through its cognate receptor, the
next logical step was to link the MAPK and PI3K/Akt
pathways to PDGF-R. To achieve this, siRNA was again
employed. PDGF-Rβ expression was knocked down
using the siRNA approach and ERK, JNK, p38, JNK and
Akt phosphorylation levels were assessed. Briefly, A172
cells were transfected with PDGF-Rβ siRNA for 24 h fol-
lowed by treatment with PDGF-BB for 1 h. As shown in
Figure 5A,B, cells transfected with PDGF-Rβ siRNA
failed to demonstrate PDGF-BB-mediated activation of
ERK, JNK, p38 and Akt. These results underpin the role
of PDGF-Rβ in PDGF-BB-mediated activation of MAPK
and PI3K/Akt pathways.
Involvement of NFκB in PDGF-BB-induced expression of
MCP-1 in astrocytes
Having determined the role of MAPK and PI3K/Akt in
PDGF-BB-mediated induction of MCP-1 expression, we
rationalized the involvement of NFκB in this process
since this transcription factor is downstream of the
aforementioned signaling mediators [31-33]. Exposure of
astrocytes to PDGF-BB resulted in a time-dependent in-
crease of p65 subunit of NFκB in the nucleus with a
concomitant transient increase in cytosolic pIκB
(Figure 6A). Validation of the role of NFκB was further
determined by pretreating astrocytes with the IκB path-
way inhibitor (SC514), followed by PDGF-BB treatment
for 24 h. As shown in Figure 6B, SC514 inhibited PDGF-
BB-mediated induction of MCP-1, thereby underscoring
the role of NFκB in this process.
To corroborate the findings found using the pharma-
cological inhibitors these cells were then transduced
with either WT or DN adenoviral constructs of NFκB.
As shown in Figure 6C, transduction with DN form of
NFκB resulted in inhibition of PDGF-BB-mediated in-
duction of MCP-1. Transduction with the WT NFκB
construct, however, and as expected, demonstrated
PDGF-BB-mediated induction of MCP-1. Together,
these findings underpin the role of NFκB in PDGF-BB-
mediated induction of MCP-1 in astrocytes.
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Since NFκB is a transcription factor that mitigates its
effects on target genes by binding to promoter regions,
we next sought to confirm the binding of NFκB with
MCP-1 promoter in its natural chromatin context by
ChIP assay to reveal active sites accessible to NFκB.
A172 cells were treated with PDGF-BB for 1 h followed
by RNA extraction and processed using a ChIP analysis
kit. These experiments revealed increased binding of
NFκB to the MCP-1 promoter in A172 cells treated with
PDGF-BB (Figure 6D,E) and, along with preceding data,
substantiate the role of NFκB in PDGF-BB-mediated
regulation of MCP-1 in astrocytes.
Figure 4 Platelet-derived growth factor (PDGF)-BB-mediated induction of monocyte chemoattractant protein 1 (MCP-1) expression
involves mitogen-activated protein kinases (MAPKs) and phosphatidylinositol 3-kinase (PI3K)/Akt cell signaling pathways. (A) Western
blot analysis of time-dependent activation of extracellular-signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), P38 and Akt by PDGF-BB.
(B) Inhibition of the ERK, JNK, p38 and Akt pathways by mitogen-activated protein (MAP) kinase kinase (MEK)1/2 (U0126), JNK (SP600125),
p38 (SB20358) and PI3K (LY294002) inhibitors resulted in amelioration of PDGF-BB-mediated induction of MCP-1 expression in astrocytes.
(C) Transfection with dominant-negative (DN)-MEK but not wild-type (WT)-MEK resulted in abrogation of PDGF-BB-mediated induction of
MCP-1. (D) Transduction with DN-Akt but not WT-Akt also resulted in abrogation of PDGF-BB-mediated induction of MCP-1. All the data are
presented as mean ± SD of three individual experiments. *P <0.05, **P <0.01, ***P <0.001 versus control group; #P <0.05, ###P <0.001 versus
PDGF-BB-treated group.
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MAPK and PI3K/Akt cell signaling pathways lie upstream
of PDGF-BB induced NFκB in astrocytes
Having determined the involvement of ERK1/2, JNK and
p38 MAPKs and NFκB in PDGF-BB-mediated MCP-1
the next logical step was to examine whether there
existed a link that could tie together the activation of
MAP kinase and Akt pathways with NFκB. Astrocytes
were transfected with either the WT or DN constructs
of MEK prior to PDGF-BB treatment as described
before. Nuclear fractions were extracted and NFκB
phosphorylation was assessed via western blotting. PDGF-
BB-mediated induction of NFκB was attenuated by DN-
MEK, but not by WT-MEK construct (Figure 7A). To
confirm the role of PI3K/Akt in PDGF-BB-mediated
NFκB, A172 cells were transduced with adenoviral con-
structs containing either WT or DN forms of Akt, trea-
ted with PDGF-BB and assessed for NFκB expression. As
shown in Figure 7B, cells transduced with DN Akt con-
struct failed to upregulate NFκB unlike the cells trans-
duced with the WT Akt construct. These findings thus
linked PDGF-BB-mediated activation of MAP kinase and
Akt pathways to the downstream activation of NFκB.
MCP-1 released from astrocytes increases monocyte
transmigration in human brain microvascular endothelial
cells
Having determined the induction of MCP-1 by PDGF-
BB, the next step was to explore the functional relevance
of this upregulation. Since MCP-1 is a known chemo-
attractant, we hypothesized that PDGF-BB-induced
MCP-1 released from the astrocytes could, in fact, act
on neighboring endothelial cells altering their function.
Human astrocytes were exposed to PDGF-BB for 2 h
then replaced with fresh media and incubated for 24 h.
Endothelial cells were grown on the upper compartment
of transwell plates and spent media was added to the
lower compartment overnight. Labeled human mono-
cytes were added to the upper compartment for 24 h
and monocyte transmigration was assessed. As shown in
Figure 8, conditioned media from primary astrocytes
Figure 5 Involvement of platelet-derived growth factor (PDGF)-Rβ in the regulation of mitogen-activated protein kinases (MAPKs) and
phosphatidylinositol 3-kinase (PI3K)/Akt cell signaling pathways. (A) Whole cell lysates from A172 cells transfected with either nonsense
(Non) or PDGF-Rβ short interfering (si)RNAs were subjected to immunoblot analysis using antibodies specific for MAPKs and PI3K/Akt signaling.
PDGF-Rβ siRNA, but not Non siRNA inhibited PDGF-BB-mediated phosphorylation of extracellular-signal-regulated kinase (ERK), c-Jun N-terminal
kinase (JNK), p38 and Akt pathways. All the data are presented as mean ± SD of three individual experiments. **P <0.01, ***P <0.001 versus
control group, ##P <0.01, ###P <0.001 versus PDGF-BB-treated group.
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cells treated with PDGF-BB resulted in a significant in-
crease in monocyte transmigration of endothelial cells,
an effect that was blocked by PDGF-R blocker STI-571.
Since monocytes express the MCP-1 receptor CCR2
[34,35], the next step was to determine whether
increased MCP-1 was also able to enhance monocyte
migration. Also shown in Figure 8A, conditioned media
from primary astrocytes cells treated with PDGF-BB
resulted in a dramatic increase in monocyte transmigra-
tion of endothelial cells and this effect was ameliorated
in conditioned media treated with the MCP-1 neutralizing
antibody. These findings thus confirm that MCP-1 was
involved in PDGF-BB-mediated disruption of the endo-
thelial barrier permeability and not only underpin the role
of MCP-1 in BBB breakdown, but reveal a vital role that
activated astrocytes play in BBB disruption and HAND
pathogenesis.
Discussion
Antiretroviral therapies have proven highly effective in
controlling systemic viral infection, thus leading to
increased longevity in patients with AIDS. The inability
Figure 6 Platelet-derived growth factor (PDGF)-BB-mediated induction of monocyte chemoattractant protein 1 (MCP-1) expression
involves nuclear factor κB (NFκB) activation. (A) Exposure of A172 cells to PDGF-BB resulted in a time-dependent increase in phosphorylation
of the p65 subunit of NFκB in the nuclear cellular fraction. Reciprocally, PDGF-BB exposure resulted in a time-dependent increase in inhibitor of
κBα (IκBα) phosphorylation in the cytosolic cellular fraction of A172 astrocytes. (B) Pretreatment with the IκBα inhibitor, SC514 resulted in
inhibition of PDGF-BB-mediated induction of MCP-1. (C) Transduction with mutant-NFκB but not wild-type (WT)-NFκB resulted in abrogation of
PDGF-BB-mediated induction of MCP-1. All the data are presented as mean ± SD of three individual experiments. ***P <0.001 versus control
group, #P <0.05, ###P <0.001 versus PDGF-BB-treated group. (D) Schematic illustration of NFκB binding consensus sequence on the promoter
region of MCP-1. (E) Chromatin immunoprecipitation (ChIP) assay demonstrating PDGF-BB-mediated binding of p65NFκB to the MCP-1 promoter.
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of some of these drugs to cross the BBB results in slow
and smoldering infection in the CNS. Subsequently, the
brain becomes a sanctuary of virus-induced toxicity
leading to increased prevalence of HAND in HIV-
infected individuals. One of the hallmark features of
HAND is increased astrogliosis comprising of increased
numbers of activated astrocytes, culminating ultimately
into increased neuronal degeneration. It is well recog-
nized that activation of astrocytes leads to the release of
a barrage of inflammatory mediators such as PDGF-BB.
PDGF-BB has been implicated in a variety of patho-
logical conditions; however, its role in HIV pathogenesis
remains less clear.
In the present study we demonstrate that HIV-1-
mediated induction of MCP-1, a potent chemokine vital
to the sustained proinflammatory response in HIV-1
pathogenesis, is regulated by PDGF-BB. To determine
the implication of increased PDGF-BB we demonstrated
that PDGF-BB treatment of human astrocyte cell line
and primary cultures resulted in induction of MCP-1
and this process was mediated via the binding of PDGF-
BB to its cognate PDGF-Rβ. These findings are consist-
ent with the reports on PDGF-mediated induction of
MCP-1 in other cell types such as the fibroblast cell line
and smooth muscle cells [36,37]. In our efforts to dissect
the upstream signaling events that are involved in MCP-
1 release from astrocytes, using both the pharmaco-
logical as well as genetic approaches we demonstrated
the role of MAPK and PI3K/Akt in PDGF-BB-mediated
induction of MCP-1 from astrocytes. The involvement
of MAPK and PI3K/Akt pathways in the induction of
MCP-1 expression are in agreement with the role these
pathways play in induction of this chemokine in other
cell types including osteoblasts, mesangial cells and
endothelial cells [38-40]. The transcription factor, NFκB
is known to play a key role in PDGF-BB signaling
and also in the expression of proinflammatory cytokines/
chemokines including MCP-1 [31,33,41]. Consistent with
other reports, our studies also revealed that PDGF-BB-
mediated induction of MCP-1 involved both NFκB acti-
vation and its binding to the MCP-1 promoter.
It was next of interest to explore the functional rele-
vance of PDGF-BB-mediated induction of MCP-1. Based
on the proximity of astrocytes to the endothelial barrier,
we rationalized that induced expression of MCP-1 in
PDGF-BB treated astrocytes could play a role in barrier
Figure 7 Mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt cell signaling pathways lie upstream of
platelet-derived growth factor (PDGF)-BB induced nuclear factor κB (NFκB) in astrocytes. The nuclear fractions of A172 cells transfected
with wild-type (WT) or dominant-negative (DN) forms of mitogen-activated protein (MAP) kinase kinase (MEK) and Akt were subjected to
western blot analysis for NFκB. (A) Transfection with DN-MEK but not WT-MEK resulted in abrogation of PDGF-BB-mediated induction of
NFκB phosphorylation. (B) Transduction with DN-Akt but not WT-Akt also resulted in abrogation of PDGF-BB-mediated induction of NFκB
phosphorylation. All the data are presented as mean ± SD of three individual experiments. ***P <0.001 versus control group, ###P <0.001 versus
PDGF-BB-treated group.
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integrity. Intriguingly, conditioned media from PDGF-
BB treated astrocytes did indeed increase monocyte
transmigration and this effect was attributable to MCP-1
as demonstrated in the blocking antibody experiments.
This role of MCP-1 is in agreement with the findings
reported by Eugenin et al. who have demonstrated that
HIV-infected leukocyte transmigration across a tissue
culture model of human BBB involved MCP-1 [42]. In
addition to disrupting the barrier permeability, MCP-1
also manifested increased monocyte recruitment. This
latter function is in keeping with its known roles both as
a chemoattractant and as a biomarker of HIV neuro-
pathogenesis [42,43].
The function of MCP-1 demonstrated in this study
can have ramifications in the pathogenesis of HAND.
Based on the proximity of astrocytes to the endothelium
and their ability to secrete both PDGF-BB and the che-
mokine MCP-1 as well as their abundance in the CNS, it
can be argued that during HIV-1 infection, viral proteins
can initiate a toxic cascade that can be self-perpetuating.
HIV-1/HIV-1 Tat can trigger increased expression of
PDGF-BB, which in turn, can lead to increased MCP-1
expression that can manifest as an amplified influx of
monocytes into the CNS. PDGF-BB has already been
shown to disrupt the BBB [19] and a similar function
has been demonstrated for MCP-1 [42]. Therefore the
release of both these mediators can independently
disrupt the endothelial barrier while enhancing neuroin-
flammation [19,42], which can have serious ramifications
in HAND.
In summary, our studies have mapped out a detailed
molecular pathway of PDGF-BB-mediated MCP-1 ex-
pression in astrocytes involving ERK1/2, JNK MAPK ac-
tivation, with the subsequent activation of NFκB
resulting in increased MCP-1 expression, ultimately
leading to increased monocyte transmigration and
increased permeability in the brains of individuals
infected with HIV.
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